News & Media

AI tool detects early signs of eye disease 1024 683 Toku Eyes

AI tool detects early signs of eye disease

The trial of an Artificial Intelligence retinal screening tool, developed in New Zealand, showed it did not miss any referable disease for diabetic patients at risk of eye disorders. THEIA…

read more
Advice from a clear-sighted entrepreneur 1024 683 Toku Eyes

Advice from a clear-sighted entrepreneur

Ehsan Vaghefi has been a guide all his life. After all, when other children his age were being helped across the street by their parents, he was helping his blind…

read more
A New Zealand startup using AI to detect eye disease raises $3.35 million 1024 683 Toku Eyes

A New Zealand startup using AI to detect eye disease raises $3.35 million

New Zealand startup Toku Eyes, which has built an artificial intelligence platform to improve early detection of eye diseases such as macular degeneration, glaucoma and other diseases observable via the…

read more
Top scores for Kiwi AI screening tool 1024 683 Toku Eyes

Top scores for Kiwi AI screening tool

Toku Eyes has completed its first prospective clinical trial of its artificial intelligence (AI) screening platform Theia, designed to support more cost-effective diagnosis and prognosis of eye disorders. The trial,…

read more
Toku Eyes raises millions for AI Tech that helps stop diabetes, preventable blindness 1024 683 Toku Eyes

Toku Eyes raises millions for AI Tech that helps stop diabetes, preventable blindness

Auckland startup Toku Eyes has raised $3.6 million to develop its AI software – which founder Dr Ehsan Vaghefi says can analyse eye images faster than a human clinician and…

read more
A multi-center prospective evaluation of THEIA 1024 683 Toku Eyes

A multi-center prospective evaluation of THEIA

A multi-center prospective evaluation of THEIA to detect diabetic retinopathy (DR) and diabetic macular edema (DME) in the New Zealand screening program Purpose: to assess the efficacy of THEIA, an…

read more

Ask us about your health screening requirements

    Dr. Ehsan Vaghefi, CEO